摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(11aS)-2,3,5,10,11,11a-hexahydro-1H-pyrrolo<2,1-c><1,4>benzodiazepin-5,11-dione | 154802-75-2

中文名称
——
中文别名
——
英文名称
(11aS)-2,3,5,10,11,11a-hexahydro-1H-pyrrolo<2,1-c><1,4>benzodiazepin-5,11-dione
英文别名
(11aR)-2,3-dihydro-1H-pyrrolo[2,1-c][1,4]benzodiazepine-5,11(10H,11aH)-dione;(11aR)-pyrrolo[2,1-c][1,4]benzodiazepine;(11AR)-1,2,3,10,11,11a-hexahydro-5H-pyrrolo[2,1-c][1,4]benzodiazepin-5,11-dione;(6aR)-6a,7,8,9-tetrahydro-5H-pyrrolo[2,1-c][1,4]benzodiazepine-6,11-dione
(11aS)-2,3,5,10,11,11a-hexahydro-1H-pyrrolo<2,1-c><1,4>benzodiazepin-5,11-dione化学式
CAS
154802-75-2
化学式
C12H12N2O2
mdl
——
分子量
216.239
InChiKey
MXBNEEHQIDLPLQ-SNVBAGLBSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    209-211 °C(Solv: ethanol (64-17-5))
  • 沸点:
    477.4±34.0 °C(Predicted)
  • 密度:
    1.35±0.1 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    0.9
  • 重原子数:
    16
  • 可旋转键数:
    0
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.33
  • 拓扑面积:
    49.4
  • 氢给体数:
    1
  • 氢受体数:
    2

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    (11aS)-2,3,5,10,11,11a-hexahydro-1H-pyrrolo<2,1-c><1,4>benzodiazepin-5,11-dione 在 sodium tetrahydroborate 、 三氟乙酸 作用下, 以 乙二醇二甲醚 为溶剂, 反应 4.0h, 以95%的产率得到(11aR)-1,2,3,10,11,11a-hexahydro-5H-pyrrolo-<2,1-c><1,4>benzodiazepin-5-one
    参考文献:
    名称:
    Novel vasopressin V2 receptor-selective antagonists, pyrrolo[2,1-a]quinoxaline and pyrrolo[2,1-c][1,4]benzodiazepine derivatives
    摘要:
    The intent of the work was to study the structure-activity relationships of AVP receptor antagonists bearing a chiral ring as a partial structure since such studies had been reported for only achiral compounds. In the present paper, we deal with compounds consisting of the chiral tricyclic hetero ring (1,2,3,3a,4,5-hexahydropyrrolo[1,2-a]quinoxaline and 1,2,3,10,11,11a-hexahydro- 1H-pyrrolo[2,1-c][1,4]benzodiazepine) and 2-phenylbenzanilide analogues. These compounds exhibited a highly selective affinity for V2 receptor, and their stereochemical configuration had a great influence on V2 receptor binding. VP-343 (N-[4[(2S,3aR)-2-hydroxy-2,3,3a,4-tetrahydropyrrolo[1,2-a]quinoxalin-5 VP-365 (N-[4-[(11aS)-2,3,11,11a-tetrahydro-1H-pyrrolo[2,1-c][1,4]benzodiazepin-10(5H)-yl]carbonyl]phenyl][1,1'-biphenyl]-2-carboxamide)) and VP-339 (N-[4-[(11aS)-5-oxo-2,3,11,11a-tetrahydro-1H-pyrrolo[2,1-c][1,4]benzodiazepin-10(5H)-yl]carbonyl]phenyl]-[1,1'-biphenyl]-2-carboxamide) were the most potent compounds in vitro and in vivo. The IC50 values of VP-343, VP-365 and VP-339 against V2 receptor were 0.772, 1.18 and 0.216 nM, respectively. The ED300 values (dose required to increase three times the urine volume of the control rats; oral administration) of VP-343, VP-365 and VP-339 were 0.22, 0.31 and 0.78 mg/kg, respectively. (C) 1999 Elsevier Science Ltd. All rights reserved.
    DOI:
    10.1016/s0968-0896(99)00049-8
  • 作为产物:
    描述:
    (11aS)-1,2,3,11a-tetrahydro-11-methoxy-5H-pyrrolo<2,1-c><1,4>benzodiazepin-5-one 为溶剂, 反应 0.5h, 以91%的产率得到(11aS)-2,3,5,10,11,11a-hexahydro-1H-pyrrolo<2,1-c><1,4>benzodiazepin-5,11-dione
    参考文献:
    名称:
    吡咯的合成[2,1- c ^ ] [1,4]苯二氮经由分子内氮杂Wittig反应。抗生素DC-81的合成
    摘要:
    使用适当取代的N-(2-叠氮基苯甲酰基)的分子内氮杂Wittig反应作为关键步骤,进行了吡咯并[2,1- c ] [1,4]苯并二氮杂ring环系统的新型高效合成。吡咯烷-2-羧醛。母体未取代的PBD 4和天然产物DC-81已以亚胺形式制备,并具有良好的总收率。
    DOI:
    10.1016/0040-4020(95)00222-t
点击查看最新优质反应信息

文献信息

  • Biphenyl derivatives and drug composition
    申请人:Wakamoto Pharmaceutical Co., Ltd.
    公开号:US06225306B1
    公开(公告)日:2001-05-01
    A biphenyl derivative represented by the following general formula (1) and a pharmaceutically acceptable salt thereof: [In the formula (1), A represents a single bond, —CH2—, —CO—, —CS— or —SO2—; B represents a single bond or —CH2—; R1 represents a hydrogen atom, —OH, —NR11R12 (wherein R11 and R12 each independently represents a hydrogen atom or an alkyl group having 1 to 4 carbon atoms), —OCOCH3, or a halogen atom; R2 represents a hydrogen atom or R1 and R2 form a group ═O together; R3 represents a hydrogen atom or an alkyl group having 1 to 4 carbon atoms; provided that in the formula, the absolute configuration of the position a may be either R or S]. The compound of the present invention has considerably high safety and efficacy and is useful as, in particular, a vasopressin receptor antagonist.
    由以下一般式(1)表示的联苯衍生物和其药学上可接受的盐:[在式(1)中,A代表单键,—CH2—,—CO—,—CS—或—SO2—;B代表单键或—CH2—;R1代表氢原子,—OH,—NR11R12(其中R11和R12各自独立地代表一个氢原子或具有1至4个碳原子的烷基基团),—OCOCH3或卤素原子;R2代表氢原子或R1和R2共同形成一个羟基;R3代表氢原子或具有1至4个碳原子的烷基基团;在该式中,位置a的绝对构型可以是R或S]。本发明的化合物具有相当高的安全性和有效性,并且特别适用作为抗利尿激素受体拮抗剂。
  • Improved Method for Microwave-Assisted Synthesis of Benzodiazepine-2,5-diones from Isatoic Anhydrides Mediated by Glacial Acetic Acid
    作者:Armando De La Cruz、Carlos Alejandro Vega-Acevedo、Ignacio Rivero、Daniel Chávez
    DOI:10.21577/0103-5053.20180031
    日期:——
    1 H NMR (200 MHz, DMSO-d6) δ 3.58 (d, 2H, J 5.6 Hz, CH2), 7.10 (brd, 1H, J 8.0 Hz, H-9), 7.21 (ddd, 1H, J 8.0, 8.0, 1.2 Hz, H-7), 7.51 (ddd, 1H, J 8.0, 8.0, 1.6 Hz, H-8), 7.75 (dd, 1H, J 8.0, 1.6 Hz, H-6), 8.57 (t, 1H, J 5.6 Hz, NH-4), 10.37 (s, 1H, NH-1); 13 C NMR (50 MHz, DMSO-d6) δ 49.5, 126.0, 129.0, 130.6, 135.9, 137.4, 142.2, 173.2, 176.2; EIMS m/z (rel. int. %): [M] + 176 (100), 147 (51), 119
    1 H NMR(200 MHz,DMSO-d6)δ3.58(d,2H,J 5.6 Hz,CH2),7.10(brd,1H,J 8.0 Hz,H-9),7.21(ddd,1H,J 8.0,8.0) ,1.2 Hz,H-7),7.51(ddd,1H,J 8.0、8.0、1.6 Hz,H-8),7.75(dd,1H,J 8.0、1.6 Hz,H-6),8.57(t,1H ,J 5.6 Hz,NH-4),10.37(s,1H,NH-1); 13 C NMR(50 MHz,DMSO-d6)δ49.5,126.0,129.0,130.6,135.9,137.4,142.2,173.2,176.2; EIMS m / z(相对于%):[M] + 176(100),147(51),119(54),92(34)。光谱数据与文献报道的一致。1-3
  • Sugar-Based Enantiomeric and Conformationally Constrained Pyrrolo[2,1-<i>c</i>][1,4]-Benzodiazepines as Potential GABA<sub>A</sub> Ligands
    作者:Ana C. Araújo、Amélia P. Rauter、Francesco Nicotra、Cristina Airoldi、Barbara Costa、Laura Cipolla
    DOI:10.1021/jm101244n
    日期:2011.3.10
    Synthesis of a library of pyrrolo[2,1-c][1,4]-benzodiazepines derived from spiro bicyclic d- or l-proline analogues containing a d- or l-fructose moiety was developed. The l-fructose moiety was obtained by using a new synthetic pathway starting from l-arabinose through a six steps synthesis in 18% overall yield. Molecular modeling calculations and DNMR studies showed that d- and l-fructose-based p
    开发了合成的吡咯并[2,1- c ] [1,4]-苯并二氮杂卓文库,该文库衍生自含有d-或l-果糖部分的螺双环d-或l-脯氨酸类似物。该升通过使用从开始一个新的合成途径获得-fructose部分升通过六步合成在18%的总收率-arabinose。分子建模计算和DNMR研究表明,基于d和l-果糖的吡咯并苯并二氮杂exhibit具有刚性的(P)-和(M)-螺旋构象,其中C-11a取代基始终是伪赤道的。另外,在苯环中用氯,溴,硝基或氨基官能化的吡咯并苯并二氮杂with具有或不具有N-甲基化并且具有或不具有糖醇基团的保护,允许建立分子结构与生物学活性之间的关系。地西epa环的构型不是影响结合亲和力的唯一关键因素,并且在某些情况下糖部分可以增加结合活性,可能是通过参与结合事件来实现的。最后,这些化合物增加了对GABA A上(M)-/(P)-螺旋苯并二氮杂类的区别识别的认识。 受体。
  • Design and synthesis of anti–inflammatory 1,2,3–triazolylpyrrolobenzodiazepinone derivatives and impact of molecular structure on COX–2 selective targeting
    作者:Amit Kumar、Mohammad Sarwar Alam、Hinna Hamid、Vaishali Chugh、Tanvi Tikla、Rajeev Kaul、Abhijeet Dhulap、Sunil K. Sharma
    DOI:10.1016/j.molstruc.2022.134151
    日期:2023.1
    process. Therapeutic utilization of selective COX–2 inhibitors has been considered an effective approach for treating inflammation with emasculated side effects. This study describes the design and enantioselective synthesis of a library of twenty–six novel 1,2,3–triazolylpyrrolobenzodiazepinone derivatives. The molecules were found to exhibit good drug–like properties as implied by the ADMET studies. Nine
    COX-2 是一种关键酶,可催化花生四烯酸转化为前列腺素的限速步骤,在炎症过程中起关键作用。选择性 COX-2 抑制剂的治疗利用已被认为是治疗具有去势副作用的炎症的有效方法。本研究描述了 26 种新型 1,2,3-三唑基吡咯并苯并二氮杂酮衍生物库的设计和对映选择性合成。正如 ADMET 研究所暗示的,这些分子被发现表现出良好的药物样特性。评估了库中九种在计算机研究中显示出可喜结果的化合物对 HeLa 细胞的细胞毒性和体外COX-1/COX-2 酶抑制作用。化合物(2b)和(4l)与标准相比,发现在体外显着抑制 COX-2 ,具有 S-几何形状的化合物 ( 4l)显示出非凡的 COX-2 抑制作用 (IC 50  = 18.9 nM) 和最佳选择性 (COX-1/COX-2 = 1060)。( 4l)与标准药物(吲哚美辛和塞来昔布)相比,在体内也表现出最有效的抗炎活性,而不会引起任何胃溃疡。分子模型研究有助于理解该化合物与
  • BIPHENYL DERIVATIVES AND MEDICINAL COMPOSITIONS
    申请人:Wakamoto Pharmaceutical Co., Ltd.
    公开号:EP0987266A1
    公开(公告)日:2000-03-22
    A biphenyl derivative represented by the following general formula (1) and a pharmaceutically acceptable salt thereof: [In the formula (1), A represents a single bond, -CH2-, -CO-, -CS- or -SO2-; B represents a single bond or -CH2-; R1 represents a hydrogen atom, -OH, -NR11R12 (wherein R11 and R12 each independently represents a hydrogen atom or an alkyl group having 1 to 4 carbon atoms), -OCOCH3, or a halogen atom; R2 represents a hydrogen atom or R1 and R2 form a group =O together; R3 represents a hydrogen atom or an alkyl group having 1 to 4 carbon atoms; provided that in the formula, the absolute configuration of the position a may be either R or S]. The compound of the present invention has considerably high safety and efficacy and is useful as, in particular, a vasopressin receptor antagonist.
    由以下通式(1)代表的联苯衍生物及其药学上可接受的盐: [在式(1)中,A代表单键、-CH2-、-CO-、-CS-或-SO2-;B代表单键或-CH2-;R1代表氢原子、-OH、-NR11R12(其中R11和R12各自独立地代表氢原子或具有1至4个碳原子的烷基)、-OCOCH3或卤素原子;R2 代表氢原子或 R1 和 R2 共同形成一个基团 =O;R3 代表氢原子或具有 1 至 4 个碳原子的烷基;但在式中,a 位的绝对构型可以是 R 或 S]。本发明的化合物具有相当高的安全性和有效性,尤其可用作血管加压素受体拮抗剂。
查看更多